ES2227671T3 - Uso de una texafirina en la preparacion de un medicamento para usar con un agente quimioterapeutico en la quimiosensibilizacion del cancer. - Google Patents

Uso de una texafirina en la preparacion de un medicamento para usar con un agente quimioterapeutico en la quimiosensibilizacion del cancer.

Info

Publication number
ES2227671T3
ES2227671T3 ES97903873T ES97903873T ES2227671T3 ES 2227671 T3 ES2227671 T3 ES 2227671T3 ES 97903873 T ES97903873 T ES 97903873T ES 97903873 T ES97903873 T ES 97903873T ES 2227671 T3 ES2227671 T3 ES 2227671T3
Authority
ES
Spain
Prior art keywords
texaphyrin
iii
use according
metal cation
chemotherapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97903873T
Other languages
English (en)
Spanish (es)
Inventor
Richard A. Miller
Stuart W. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacyclics LLC
Original Assignee
Pharmacyclics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics LLC filed Critical Pharmacyclics LLC
Application granted granted Critical
Publication of ES2227671T3 publication Critical patent/ES2227671T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ES97903873T 1996-01-25 1997-01-23 Uso de una texafirina en la preparacion de un medicamento para usar con un agente quimioterapeutico en la quimiosensibilizacion del cancer. Expired - Lifetime ES2227671T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/591,318 US5776925A (en) 1996-01-25 1996-01-25 Methods for cancer chemosensitization
US591318 1996-01-25

Publications (1)

Publication Number Publication Date
ES2227671T3 true ES2227671T3 (es) 2005-04-01

Family

ID=24366012

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97903873T Expired - Lifetime ES2227671T3 (es) 1996-01-25 1997-01-23 Uso de una texafirina en la preparacion de un medicamento para usar con un agente quimioterapeutico en la quimiosensibilizacion del cancer.

Country Status (13)

Country Link
US (1) US5776925A (enExample)
EP (1) EP0912196B9 (enExample)
JP (1) JP2000503989A (enExample)
KR (1) KR19990082024A (enExample)
CN (1) CN1093766C (enExample)
AT (1) ATE277637T1 (enExample)
AU (1) AU715025B2 (enExample)
DE (1) DE69730961T2 (enExample)
ES (1) ES2227671T3 (enExample)
IL (1) IL125459A0 (enExample)
NO (1) NO983429L (enExample)
NZ (1) NZ331513A (enExample)
WO (1) WO1997026915A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US6482436B1 (en) 1993-01-29 2002-11-19 Ferx Incorporated Magnetically responsive composition
US6200547B1 (en) * 1994-01-26 2001-03-13 Ferx Incorporated Magnetically responsive compositions for carrying biologically active substances and methods of production and use
US5969111A (en) * 1994-04-14 1999-10-19 Board Of Regents, The University Of Texas System Texaphyrins substituted with imidazole are provided
RU2106146C1 (ru) 1995-07-17 1998-03-10 Институт элементоорганических соединений РАН Средство для подавления опухолевого роста
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
JPH10279502A (ja) * 1997-03-31 1998-10-20 Katsuro Tachibana 光感受性物質の励起方法
US6022526A (en) * 1997-07-30 2000-02-08 Pharmacyclics, Inc. Use of texaphyrins in detection of melanin and melanin metabolites diagnostic of melanotic melanoma
EP1140198B1 (en) 1999-01-13 2007-10-31 Alchemia Oncology Pty Limited Use of hyaluronan for the manufacture of a medicament for the enhancement of the efficacy of cytotoxic drugs
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
AU1233701A (en) * 1999-10-29 2001-05-14 Board Of Regents, The University Of Texas System Methods and compositions for treating atheroma, tumors and other neoplastic tissue
US7579338B2 (en) * 1999-10-29 2009-08-25 Pharmacyclics, Inc. Methods and compositions for treating atheroma, tumors and other neoplastic tissues
US20030031676A1 (en) * 1999-10-29 2003-02-13 Pharmacyclics, Inc. Conjugate compounds for treating atheroma and other diseases
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
US6638924B2 (en) 2000-08-30 2003-10-28 Pharmacyclics, Inc. Metallotexaphyrin derivatives
US7449454B2 (en) * 2000-08-30 2008-11-11 Pharmacyclics, Inc. Metallotexaphyrin derivatives
US7112671B2 (en) * 2000-08-30 2006-09-26 Pharmacyclics, Inc. Non-symmetric tripyrranes in the synthesis of novel macrocycles
US20030188326A1 (en) 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
EP1345606A4 (en) 2000-11-17 2005-02-09 Pharmacyclics Inc TEXAPHYRINE COORDINATION COMPOUNDS AND THEIR USE
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
US6630454B2 (en) 2001-09-10 2003-10-07 Ramot At Tel-Aviv University Ltd. Method and pharmaceutical composition for the treatment of cancer
EP1451343B1 (en) 2001-11-02 2012-10-17 Dana-Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective dna repair mechanisms and treatment thereof
CA2469615A1 (en) * 2001-12-13 2003-06-19 Qing Fan Combination cancer therapy
DE60229437D1 (de) * 2001-12-13 2008-11-27 Pharmacyclics Inc Verfahren zur beeinflussung neurologischer progression
WO2003072581A1 (en) 2002-02-26 2003-09-04 Board Of Regents, The University Of Texas System Cyclo[n]pyrroles and methods thereto
US6723750B2 (en) 2002-03-15 2004-04-20 Allergan, Inc. Photodynamic therapy for pre-melanomas
US20030224422A1 (en) * 2002-04-08 2003-12-04 St. Jude Children's Research Hospital, Inc. Pre-and post therapy gene expression profiling to identify drug targets
US20040010218A1 (en) * 2002-07-11 2004-01-15 Henderson Barbara W. Photodynamic therapy for the enhancement of vascular permeability to aid in drug delivery to diseased tissues
JP2004077714A (ja) * 2002-08-15 2004-03-11 Fuji Xerox Co Ltd 光走査装置
US7981928B2 (en) 2002-09-05 2011-07-19 Nanodynamics, Inc. Chemotherapy method using x-rays
WO2005112759A1 (en) * 2004-05-20 2005-12-01 Pharmacyclics, Inc. A method of enhancing visualization of atherosclerotic plaque
JP2006224318A (ja) * 2005-02-15 2006-08-31 Brother Ind Ltd インクジェット記録装置
EP1704870A1 (en) 2005-03-25 2006-09-27 Nipro Corporation Use of iron compounds as radiosensitizers
JP4972929B2 (ja) * 2005-03-25 2012-07-11 ニプロ株式会社 放射線増感剤
CA2616607C (en) * 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
US8319625B2 (en) * 2005-09-01 2012-11-27 Simplexgrinnell Lp Fire alarm textual notification related application
EP1922077A4 (en) * 2005-09-07 2013-03-06 Alchemia Oncology Pty Ltd THERAPEUTIC COMPOSITIONS WITH HYALURON AND THERAPEUTIC ANTIBODIES AND TREATMENT PROCEDURES
US20070072838A1 (en) * 2005-09-26 2007-03-29 Pharmacyclics, Inc. High-purity texaphyrin metal complexes
US20070078119A1 (en) * 2005-09-30 2007-04-05 Pharmacyclics, Inc. Storage system for texaphyrin pharmaceutical formulations
WO2008000079A1 (en) * 2006-06-26 2008-01-03 The University Of British Columbia Secreted protein acidic and rich in cysteine (sparc) as chemotherapeutic sensitizers
US8287839B2 (en) * 2006-12-04 2012-10-16 Brookhaven Science Associates, Llc Carboranylporphyrins and uses thereof
US8444953B2 (en) * 2007-03-22 2013-05-21 Brookhaven Science Associates, Llc Symmetric and asymmetric halogen-containing metallocarboranylporphyrins and uses thereof
US20080279781A1 (en) * 2007-05-10 2008-11-13 Brookhaven Science Associates, Llc Glycosylated Carboranylporphyrins and Uses Thereof
RU2438718C1 (ru) * 2010-06-18 2012-01-10 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения сарком мягких тканей
TWI445696B (zh) 2010-11-29 2014-07-21 Univ Nat Yang Ming 標靶人類胸線核苷酸激酶誘導惡性腫瘤中的ｄｎａ修復毒性
US9662328B2 (en) 2010-11-29 2017-05-30 National Yang-Ming University Targeting human thymidylate kinase induces DNA repair toxicity in malignant tumor cells
SG11201610306RA (en) 2014-06-11 2017-01-27 Univ Texas Texaphyrin-pt(iv) conjugates and compositions for use in overcoming platinum resistance
CA3047100A1 (en) * 2016-12-13 2018-06-21 Health Research, Inc. Near infrared (nir) photodynamic therapy (pdt) in combination with chemotherapy
WO2022036292A1 (en) 2020-08-14 2022-02-17 Board Of Regents, The University Of Texas System Texaphyrin derivatives for manganese chemotherapy, photoacoustic imaging, and photothermal therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599923A (en) * 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5252720A (en) * 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
US4935498A (en) * 1989-03-06 1990-06-19 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5559207A (en) * 1989-03-06 1996-09-24 Board Of Regents, University Of Texas Texaphyrin metal complex mediated ester hydrolysis
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5607924A (en) * 1992-01-21 1997-03-04 Pharmacyclics, Inc. DNA photocleavage using texaphyrins
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
US5714328A (en) * 1995-06-07 1998-02-03 Board Of Regents, The University Of Texas System RNA photocleavage using texaphyrins

Also Published As

Publication number Publication date
EP0912196B1 (en) 2004-09-29
AU1833397A (en) 1997-08-20
DE69730961D1 (de) 2004-11-04
JP2000503989A (ja) 2000-04-04
CN1213313A (zh) 1999-04-07
US5776925A (en) 1998-07-07
EP0912196A1 (en) 1999-05-06
NO983429D0 (no) 1998-07-24
HK1018588A1 (en) 1999-12-30
ATE277637T1 (de) 2004-10-15
NO983429L (no) 1998-09-24
DE69730961T2 (de) 2005-11-24
IL125459A0 (en) 1999-03-12
WO1997026915A1 (en) 1997-07-31
EP0912196B9 (en) 2005-01-05
NZ331513A (en) 2001-10-26
CN1093766C (zh) 2002-11-06
AU715025B2 (en) 2000-01-13
KR19990082024A (ko) 1999-11-15

Similar Documents

Publication Publication Date Title
EP0912196B9 (en) Use of a thexaphyrin in the preparation of a medicament for use with a chemotherapeutic agent in cancer chemosensitization
Gill et al. Transition metal compounds as cancer radiosensitizers
Yang et al. Illuminating platinum transportation while maximizing therapeutic efficacy by gold nanoclusters via simultaneous near-infrared-I/II imaging and glutathione scavenging
KR102778887B1 (ko) 초음파역학 시술을 위한 미세거품-화학치료제 복합체
ES2972577T3 (es) Formación de imágenes y terapia dirigidas a la proteína de activación de fibroblastos (FAP)
ES2307867T3 (es) Preparacion combinada que comprende un derivado de morfolinil antraciclina y un inhibidor de topoisomerasa ii.
ES2333400T3 (es) Composiciones y procedimientos para tratar linfonas.
ES2880291T3 (es) Nanopartículas conjugadas a un agente antinucleolina
ES2294756T3 (es) Uso de et743 en terapia de combinacion con dexametasona para el tratamiento del cancer.
ES2913119T3 (es) Cerdulatinib para tratar mieloma
JP7184775B2 (ja) 黄体化ホルモン放出ホルモン受容体（ｌｈｒｈ－ｒ）コンジュゲートおよびその使用
EA026168B1 (ru) Способы лечения рака
EP2993983B1 (en) Targeting corroles for tumor toxicity and mri
JP2010509241A (ja) 膜貫通ペプチドからなる自己凝集性ナノ粒子および抗癌剤の特異的腫瘍内送達のためのその利用
Liu et al. Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs
US6638924B2 (en) Metallotexaphyrin derivatives
US20170165382A1 (en) Nanocarriers for cancer treatment
CA2243392C (en) Use of a texaphyrin in the preparation of a medicament for use with a chemotherapeutic agent in cancer chemosensitization
KR20050026903A (ko) 암 치료에서 약물 감작제로서의 아릴옥시프로필아민
AU775680B2 (en) Liposome composition and method for administration of a radiosensitizer
HK1018588B (en) Use of a texaphyrin in the preparation of a medicament for use with a chemotherapeutic agent in cancer chemosensitization
US7449454B2 (en) Metallotexaphyrin derivatives
McGuire et al. Phase II study of esorubicin (4′-deozydoxorubicin) in advanced epithelial carcinoma of the ovary: A Gynecologic Oncology Group study
EP4727527A2 (en) Grp78 targeted liposomal nanoparticles (tlnps) for the treatment of cancer
Amin et al. Liposomal Drug Delivery Systems for Cancer Therapy: the Rotterdam Experience. Pharmaceutics 2022, 14, 2165